title: Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.
abstract: Non-tuberculous mycobacteria (NTM) infections are increasingly being reported worldwide. They are a major concern for healthcare professionals for multiple reasons, ranging from the intrinsic resistance of NTM to most conventionally utilized antimicrobials to inharmonious diagnostic criteria utilized for evaluation of NTM-infected patients, leading to high morbidity. In this review, we highlight the paucity of drugs having potent anti-NTM activity amongst the new antimicrobials currently under various stages of development for anti-tubercular activity and issue a call for the establishment of a concerted dedicated drug discovery pipeline targeting NTM.
authors.affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow 226031, Uttar Pradesh, India.
authors.forename: Isha
authors.initials: I
authors.lastname: Soni
authors.affiliation: Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: De Groote
authors.affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow 226031, Uttar Pradesh, India.
authors.forename: Arunava
authors.initials: A
authors.lastname: Dasgupta
authors.affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow 226031, Uttar Pradesh, India.
authors.forename: Sidharth
authors.initials: S
authors.lastname: Chopra
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000631:Aminopyridines / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D002986:Clinical Trials as Topic; D064687:Diarylquinolines / Q000494:pharmacology; D055808:Drug Discovery; D005029:Ethylenediamines / Q000494:pharmacology; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy; D009593:Nitroimidazoles / Q000494:pharmacology; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D010080:Oxazoles / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology; D013843:Thiazines / Q000494:pharmacology; D000078304:Tigecycline; D014529:Uridine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C540716:2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one; C530475:7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D001381:Azepines; D001549:Benzamides; C583520:CPZEN-45; D064687:Diarylquinolines; D005029:Ethylenediamines; D024841:Fluoroquinolones; C506841:N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; D010879:Piperazines; C000599107:SQ-641; D013141:Spiro Compounds; D013843:Thiazines; D000078304:Tigecycline; C493870:bedaquiline; C008599:nitromide; C000592783:macozinone; D008911:Minocycline; D000218:Adamantane; D014529:Uridine